Solid Biosciences (SLDB) Profit After Tax (2017 - 2026)

Solid Biosciences has disclosed Profit After Tax across 10 years of filings, most recently posting -$56.7 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at -$56.7 million, down 44.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$191.8 million (down 37.28% YoY), and the FY2025 annual result was -$174.3 million, down 39.78% from the prior year.
• Profit After Tax came in at -$56.7 million for Q1 2026 at Solid Biosciences, down from -$49.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$15.2 million in Q4 2022 to a low of -$56.7 million in Q1 2026.
• The 5-year median for Profit After Tax is -$25.3 million (2022), against an average of -$31.6 million.
• Peak annual rise in Profit After Tax reached 19.18% in 2024, while the deepest fall reached 109.64% in 2024.
• Solid Biosciences' Profit After Tax stood at -$15.2 million in 2022, then sank by 34.12% to -$20.3 million in 2023, then slumped by 109.64% to -$42.6 million in 2024, then retreated by 16.81% to -$49.8 million in 2025, then declined by 14.02% to -$56.7 million in 2026.
• The last three Profit After Tax figures came in at -$56.7 million (Q1 2026), -$49.8 million (Q4 2025), and -$45.8 million (Q3 2025), per Business Quant data.